This article is more than 5 years old. Information may no longer be current.
Cilostazol helps reduce recurrent femoropopliteal in-stent restenosis
Click Here to Manage Email Alerts
The administration of cilostazol after endovascular treatment for femoropopliteal in-stent restenosis reduced recurrent in-stent restenosis, according to new data published in the Journal of Endovascular Therapy.
“Recent reports have found that cilostazol reduced restenosis after [endovascular therapy] for de novo femoropoliteal stenosis, as well as amputation target lesion revascularization,” Yusuke Tomoi, MD, from the department of cardiology at Kokura Memorial Hospital in Kitakushu, Japan, and colleagues wrote. “However, no data have been published concerning the effect of cilostazol administration after treatment for femoropopliteal [in-stent restenosis].”
To investigate the effect of cilostazol after femoropopliteal in-stent restenosis (ISR) treatment on recurrent ISR, Tomoi and colleagues reviewed the database of a multicenter, retrospective, observational registry from three hospitals in Japan.
They analyzed 338 consecutive patients with a mean age of 72 years who underwent endovascular therapy for femoropopliteal ISR in 379 limbs between 2010 and 2014.
Ninety-seven patients were excluded from the study, leaving 24 patients who received cilostazol initially after ISR treatment and 217 patients who did not receive the drug.
The primary endpoint was 2-year recurrent ISR after treatment and the secondary endpoints included recurrent TLR and reocclusion at 2 years.
Researchers determined restenosis by a peak systolic velocity ratio greater than 2.4 on a duplex scan or greater than 50% stenosis on angiography.
At 2 years, freedom from recurrent ISR was higher in the cilostazol group vs. the no-cilostazol group (48.6% vs. 32.4%, P = .047).
There was no significant difference in freedom from recurrent TLR (64.7% vs 53.8%) and reocclusion (88.3% vs 73.9%) between the groups at 2 years.
Cilostazol administration was a negative predictor of recurrent ISR after researchers adjusted for prespecified risk factors (HR = 0.52; 95% CI, 0.28-0.88). – by Dave Quaile
Disclosures: The authors report no relevant financial disclosures.
Click Here to Manage Email Alerts